Cargando…

Insulin growth factor axis and cardio-renal risk in diabetic kidney disease: an analysis from the CREDENCE trial

BACKGROUND: The insulin-like growth factors (IGF) play a crucial role in regulating cellular proliferation, apoptosis, and key metabolic pathways. The ratio of IGF-1 to IGF binding protein-3 (IGFBP-3) is an important factor in determining IGF-1 bioactivity. We sought to investigate the association o...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mohebi, Reza, Liu, Yuxi, Hansen, Michael K., Yavin, Yshai, Sattar, Naveed, Pollock, Carol A., Butler, Javed, Jardine, Meg, Masson, Serge, Heerspink, Hiddo J. L., Januzzi Jr, James L.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2023
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10339517/ https://www.ncbi.nlm.nih.gov/pubmed/37438734 http://dx.doi.org/10.1186/s12933-023-01916-2

Ejemplares similares

Extremes of both weight gain and weight loss are associated with increased incidence of heart failure and cardiovascular death: evidence from the CANVAS Program and CREDENCE
por: Ferrannini, Giulia, et al.
Publicado: (2023)

Cardiorenal protective effects of canagliflozin in CREDENCE according to glucose lowering
por: Charytan, David M, et al.
Publicado: (2023)

Canagliflozin and Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus and Chronic Kidney Disease in Primary and Secondary Cardiovascular Prevention Groups: Results From the Randomized CREDENCE Trial
por: Mahaffey, Kenneth W., et al.
Publicado: (2019)

Canagliflozin, Blood Pressure Variability, and Risk of Cardiovascular, Kidney, and Mortality Outcomes: Pooled Individual Participant Data From the CANVAS and CREDENCE Trials
por: Fletcher, Robert A., et al.
Publicado: (2023)

Risk Factors for Fracture in Patients with Coexisting Chronic Kidney Disease and Type 2 Diabetes: An Observational Analysis from the CREDENCE Trial
por: Young, Tamara K., et al.
Publicado: (2022)

Effect of Canagliflozin on Total Cardiovascular Burden in Patients With Diabetes and Chronic Kidney Disease: A Post Hoc Analysis From the CREDENCE Trial
por: Li, Jing‐Wei, et al.
Publicado: (2022)

Of credence and credibility: A year gone by
por: Jain, Sanjay N
Publicado: (2014)

Commentary: Religious credence is not factual belief
por: Talmont-Kaminski, Konrad
Publicado: (2016)

Effect of SGLT2 Inhibitors on Stroke and Atrial Fibrillation in Diabetic Kidney Disease: Results From the CREDENCE Trial and Meta-Analysis
por: Zhou, Zien, et al.
Publicado: (2021)

The Use of Surrogate Endpoints in Regulating Medicines for Cardio-Renal Disease: Opinions of Stakeholders
por: Schievink, Bauke, et al.
Publicado: (2014)

Mechanistic Efficacy of Sacubitril/Valsartan in Ischemic Versus Nonischemic Heart Failure
por: Mohebi, Reza, et al.
Publicado: (2023)

Effects of the SGLT2 inhibitor canagliflozin on plasma biomarkers TNFR-1, TNFR-2 and KIM-1 in the CANVAS trial
por: Sen, Taha, et al.
Publicado: (2021)

Pharmacological credence of the folklore use of Bauhinia malabarica in the management of jaundice
por: Thenmozhi, K., et al.
Publicado: (2018)

CREDENCE: A silver lining in the dark cloud of diabetic nephropathy
por: Hanai, Ko, et al.
Publicado: (2019)

How Much Credence Does It Take? Evidence on the Trade-Off between Country-Of-Origin Information and Credence Attributes for Beef from a Choice Experiment in Sweden
por: Lagerkvist, Carl Johan, et al.
Publicado: (2017)

Sodium‐glucose co‐transporter‐2 inhibitors with and without metformin: A meta‐analysis of cardiovascular, kidney and mortality outcomes
por: Neuen, Brendon L., et al.
Publicado: (2020)

Importance of the ‘area under the curve’ from serial NT‐proBNP measurements during treatment with sacubitril/valsartan
por: Mohebi, Reza, et al.
Publicado: (2023)

How Social Preferences Shape Incentives in (Experimental) Markets for Credence Goods
por: Kerschbamer, Rudolf, et al.
Publicado: (2016)

Considering Fraud Vulnerability Associated with Credence-Based Products Such as Organic Food
por: Manning, Louise, et al.
Publicado: (2021)

Association Between Circulating GDF‐15 and Cardio‐Renal Outcomes and Effect of Canagliflozin: Results From the CANVAS Trial
por: Sen, Taha, et al.
Publicado: (2021)

Sodium glucose co-transporter 2 inhibition: a new avenue to protect the kidney
por: Heerspink, Hiddo J L
Publicado: (2019)

Survey data on consumer behaviour in olive oil markets: The role of product knowledge and brand credence
por: Salazar-Ordóñez, Melania, et al.
Publicado: (2018)

Credence in the Organization’s Ability to Respond to Change – Implications on Work Engagement and Job Satisfaction in the Church of Sweden
por: Edvik, Anders, et al.
Publicado: (2020)

Effect of the SGLT2 Inhibitor Dapagliflozin on Potassium Levels in Patients with Type 2 Diabetes Mellitus: A Pooled Analysis
por: Yavin, Yshai, et al.
Publicado: (2016)

Long-Term Safety of Dapagliflozin in Older Patients with Type 2 Diabetes Mellitus: A Pooled Analysis of Phase IIb/III Studies
por: Fioretto, Paola, et al.
Publicado: (2016)

Exposure and response analysis of aleglitazar on cardiovascular risk markers and safety outcomes: An analysis of the AleCardio trial
por: Koomen, Jeroen V., et al.
Publicado: (2019)

Epidemiology of the diabetes-cardio-renal spectrum: a cross-sectional report of 1.4 million adults
por: Schechter, Meir, et al.
Publicado: (2022)

Mitochondrial Dysfunction in the Cardio-Renal Axis
por: Mendez-Barbero, Nerea, et al.
Publicado: (2023)

Altruism and anti-anthropocentrism shape individual choice intentions for pro-environmental and ethical meat credence attributes
por: Anders, Sven, et al.
Publicado: (2023)

Renal safety of canagliflozin, a sodium glucose co‐transporter 2 inhibitor, in patients with type 2 diabetes mellitus
por: Desai, Mehul, et al.
Publicado: (2017)

Progress and opportunities in measuring the burden of Chronic Kidney Disease
por: Vart, Priya, et al.
Publicado: (2022)

Food Credence Attributes: A Conceptual Framework of Supply Chain Stakeholders, Their Motives, and Mechanisms to Address Information Asymmetry
por: Schrobback, Peggy, et al.
Publicado: (2023)

Feasibility, credence, and usefulness of out-of-office cuffless blood pressure monitoring using smartwatch: a population survey
por: Jang, Yongjun, et al.
Publicado: (2023)

High-sensitivity C-reactive protein concentrations among patients with and without diabetes in a multiethnic population of Singapore: CREDENCE Study
por: Dalan, Rinkoo, et al.
Publicado: (2010)

The effects of dapagliflozin on cardio‐renal risk factors in patients with type 2 diabetes with or without renin‐angiotensin system inhibitor treatment: a post hoc analysis
por: Scholtes, Rosalie A., et al.
Publicado: (2019)

Treating diabetic complications; from large randomized clinical trials to precision medicine
por: Heerspink, Hiddo J. L., et al.
Publicado: (2018)

Novel anti-inflammatory drugs for the treatment of diabetic kidney disease
por: Heerspink, Hiddo J. L., et al.
Publicado: (2016)

Time for clinical decision support systems tailoring individual patient therapy to improve renal and cardiovascular outcomes in diabetes and nephropathy
por: de Zeeuw, Dick, et al.
Publicado: (2020)

Effect of lowering blood pressure on cardiovascular events and mortality in patients on dialysis: a systematic review and meta-analysis of randomised controlled trials
por: Heerspink, Hiddo J Lambers, et al.
Publicado: (2009)

Rationale and Design of the CREDENCE Trial: computed TomogRaphic evaluation of atherosclerotic DEtermiNants of myocardial IsChEmia
por: Rizvi, Asim, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_v8c92ir00bf236fdtg1bog0869